Table 2.
Additional disease activity outcomes following 48 weeks of CZP 200 mg Q2W
| Disease activity measure | Week 0 (N=89) |
Week 48 (n=86) |
|---|---|---|
| ASDAS, mean (SD) | 3.5 (0.9) | 2.0 (0.9) |
| ASDAS disease activity,* n (%) | ||
| Inactive disease | 0 (0) | 23 (27%) |
| Major improvement | – | 25 (29%) |
| Clinically important improvement | – | 53 (62%) |
| BASDAI, mean (SD) | 6.5 (1.5) | 3.3 (2.1) |
| Fatigue (BASDAI Q1), mean (SD) | 7.0 (1.8) | 4.0 (2.3) |
| BASFI, mean (SD) | 5.1 (2.4) | 2.9 (2.3) |
| Patient’s GADA, mean (SD) | 6.7 (2.2) | 3.1 (2.4) |
| Physician’s GADA, mean (SD) | 5.9 (2.1) | 1.5 (1.3) |
| Total spinal pain, mean (SD) | 6.7 (2.0) | 3.0 (2.4) |
| ASQoL, mean (SD) | 10.6 (5.1) | 5.3 (4.8) |
| ASAS HI, mean (SD) | 9.3 (5.7) | 5.2 (3.8) |
Observed data are shown.
*ASDAS inactive disease: ASDAS <1.3; ASDAS major improvement: decrease of ≥2.0 units from baseline; ASDAS clinically important improvement: decrease of ≥1.1 units from baseline.
ASAS HI, Assessment of Axial Spondyloarthritis international Society Health Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CZP, certolizumab pegol; GADA, Global Assessment of Disease Activity; Q2W, every 2 weeks.